Nuplazid ‘Encouraging’ in Lowering Dementia-related Psychosis Risk, HARMONY Trial Finds

Nuplazid ‘Encouraging’ in Lowering Dementia-related Psychosis Risk, HARMONY Trial Finds
[Editor's note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.] People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase 3 trial were almost three times less likely to have a psychosis relapse — a worsening of delusions and hallucinations — than others, HARMONY trial data show. HARMONY met its main goal, significantly lowering the risk of a psychosis relapse by 2.8 times compared to placebo, and also found most patients unlikely to discontinue Nuplazid’s use for any reason. Based on these findings, Acadia Pharmaceuticals, the manufacturer of Nuplazid, plans to meet with the U.S. Food and Drug Administration early next year to discuss the possibility of extending the medi
Subscribe or to access all post and page content.